✦ LIBER ✦

Crohn’s Disease Patients’ Risk-Benefit Preferences: Serious Adverse Event Risks Versus Treatment Efficacy

✍ Scribed by F. Reed Johnson; Semra Özdemir; Carol Mansfield; Steven Hass; David W. Miller; Corey A. Siegel; Bruce E. Sands

Book ID: 119759866
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 646 KB
Volume: 133
Category: Article
ISSN: 0016-5085
DOI: 10.1053/j.gastro.2007.04.075

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Multiple sclerosis patients—benefit-risk

Multiple sclerosis patients—benefit-risk preferences: Serious adverse event risks versus treatment efficacy

✍ F. Reed Johnson; George Van Houtven; Semra Özdemir; Steve Hass; Jeff White; Gord 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 269 KB

PGI22 WEIGHING TREATMENT BENEFITS AGAINS

PGI22 WEIGHING TREATMENT BENEFITS AGAINST TREATMENT RISKS: CROHN'S DISEASE PATIENTS'WILLINGNESS TO ACCEPT RISK-BENEFIT TRADEOFFS

✍ FR Johnson; S Özdemir; C Mansfield; BE Sands; CA Siegel; SL Hass; DW Miller; TJ 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB

PR3 PATIENTS', PARENTS', AND PHYSICIANS'

PR3 PATIENTS', PARENTS', AND PHYSICIANS' RISK-BENEFIT TRADE-OFF PREFERENCES FOR CROHN'S DISEASE TREATMENTS

✍ FR Johnson; S Ozdemir; C Mansfield; AB Hauber; SL Hass; CA Siegel; BE Sands; DW 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB

Risk–benefit analysis of adalimumab vers

Risk–benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease

✍ Edward V. Loftus Jr; Scott J. Johnson; Si-Tien Wang; Eric Wu; Parvez M. Mulani; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 474 KB 👁 1 views

Background: Adalimumab is indicated for the treatment of moderately to severely active Crohn's disease (CD). A systematic analysis of risks and benefits of adalimumab versus traditional non-biologic therapies for patients refractory to non-biologic therapy is lacking. Methods: A base-case analysis

An unusual presentation of T-lymphoma in

An unusual presentation of T-lymphoma in a Crohn's disease patient treated with combo therapy: We are willing to take a risk of serious adverse events for a doubtful benefit?

✍ Emanuele Sinagra; Claudia Romano; Roberto Virdone; Emanuele Orlando; Mario Cotto 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 380 KB

Su1159 Risk of Infections With Natalizum

Su1159 Risk of Infections With Natalizumab Therapy Among Patients With Crohn's Disease: An Analysis of the Food and Drug Administration Adverse Event Reporting System

✍ Deepak, Parakkal; Stobaugh, Derrick J.; Ehrenpreis, Eli D. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 513 KB